Equity Overview
Price & Market Data
Price: $1.22
Daily Change: $0.00 / 0.00%
Range: $1.19 - $1.24
Market Cap: $22,996,560
Volume: 72,258
Performance Metrics
1 Week: -9.20%
1 Month: -0.83%
3 Months: -14.89%
6 Months: -32.20%
1 Year: 20.01%
YTD: -33.70%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.